ANZ in Focus as Rate Bets Meet Holiday Lull

ANZ in Focus as Rate Bets Meet Holiday Lull

June 8, 2026

SYDNEY, June 9, 2026, 03:03 AEST

  • ANZ slipped 1.04% to A$34.12 at Friday’s close, the last session before the long weekend break in Australia.
  • The ASX cash market didn’t open Monday due to the King’s Birthday holiday and is set to resume trading Tuesday.
  • Investors are back in the market looking at bank margins, pressure from mortgage competition and what the Reserve Bank of Australia will do with rates on June 16.

ANZ Group Holdings shares are set to resume trading after the long weekend. The stock last finished at A$34.12, losing 1.04% on Friday and down 3.1% from the Friday before.

ASX cash equities reopen Tuesday after the King’s Birthday break, with investors facing three live drivers: Friday’s bank slide, cuts to fixed-rate mortgages from ANZ, and the Reserve Bank meeting coming up in a week. Normal ASX hours are just before 10 a.m. until 4 p.m. in Sydney, the exchange says.

ASX 200 dropped 61 points on Friday, down 0.70% to 8,625.10, falling under its 20-day moving average, according to ASX market data. The broader selloff didn’t do much to help ANZ.

ANZ spent the week moving around. After closing at A$35.05 Monday, the stock slumped Tuesday, picked up midweek, and slipped again Friday. It ended the week below last week’s A$35.20 finish.

ANZ has dropped its two- and three-year fixed home-loan rates by up to 0.10 percentage point, Canstar said Friday. The move breaks from rivals, with most lenders raising fixed rates lately. Fixed rates hold a borrower’s mortgage interest steady for a set term; variable rates shift.

ANZ ended up in the middle of the pack after the latest round of fixed rate moves. Canstar said Westpac raised some fixed rates the day before, NAB raised fixed rates last Friday, and Macquarie cut fixed rates more, putting ANZ below Macquarie but ahead of Westpac and NAB on some terms.

ANZ and Macquarie have “shifted gears,” according to Canstar Data Insights Director Sally Tindall, who said the mixed moves make clear “how uncertain the outlook remains.” For some borrowers, Tindall said, the choice to fix isn’t always about getting the lowest rate, but about “locking in certainty.” Canstar

RBA is on deck, with its Monetary Policy Board set for June 15-16. The decision statement is out at 2:30 p.m. AEST on June 16. The cash rate, which sets funding costs for Australian banks and loan rates, will be in focus.

RBA board member Ian Harper said in Melbourne last week the policy call came with plenty of uncertainty — “none of us really knows” — and flagged inflation expectations as a worry. That leaves bank stocks open to changes in bond yields or mortgage-rate bets ahead of the meeting. Reserve Bank of Australia

ANZ doesn’t have an ordinary-share dividend on the schedule this week. The company’s shareholder calendar shows June 9 as the ex-date for its June quarterly distributions on capital notes CN6, CN7, CN8 and CN9. The record date follows on June 10. These capital notes count as hybrid securities, part debt and part equity. The ex-date is when new buyers lose eligibility for that distribution.

ANZ’s turnaround under CEO Nuno Matos is still the main story for the stock. The bank posted half-year cash profit of A$3.78 billion through March 31, a 14% rise from the prior six months when excluding big one-offs. The cash profit number is ANZ’s preferred way to show underlying earnings, removing some non-core items.

Matos said the bank’s “transformation is running at pace” and that ANZ had cut duplication, kept margins steady and lifted returns, even with heavy competition. He said the “situation remains dynamic,” and noted ANZ raised collective provisions as the risk outlook worsened. ANZ

But the risk is there. Higher rates might boost some lending margins but can hit credit growth and add strain for borrowers. Lower rates could help demand but pressure bank income. ANZ has to deliver on Suncorp Bank integration and fix risk management. Its New Zealand unit also warned it could face about NZ$125 million in liability after a class-action ruling.

Stock Market Today

  • New Drug Apitegromab May Preserve Muscle Mass During Weight Loss with GLP-1 Injections
    June 8, 2026, 1:35 PM EDT. A muscle growth drug, apitegromab, could reduce loss of lean body mass in patients using weight loss GLP-1 jabs like tirzepatide (Mounjaro), a small US trial shows. Lean mass includes muscle, vital for strength, calorie burning, and diabetes risk reduction. The study involved 102 participants receiving tirzepatide with either apitegromab or placebo over 24 weeks. Apitegromab users lost 55% less lean muscle compared to placebo, despite similar total weight loss. Researchers caution the results are preliminary due to the trial's small size, short duration, and predominantly female cohort. Experts emphasize the need for larger, longer studies to verify safety and functional benefits.